Most firms to slash R&D spending in 2012 business plan

Published: 2011-11-14 06:57:00

Updated: 2011-11-14 06:57:00

A majority of Korean pharmaceutical companies are now busy finalizing their business plans for the new year, but their 2012 budget plan will place top priority on slashing their research and developing (R&D) spending as part of efforts to save the administrative and promotional expenses, industry...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK